IRIS
GIAMPIERI, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.176
EU - Europa 2.471
AS - Asia 1.239
SA - Sud America 262
AF - Africa 144
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.297
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.159
IT - Italia 432
UA - Ucraina 418
SG - Singapore 354
RU - Federazione Russa 318
CN - Cina 308
IE - Irlanda 308
SE - Svezia 304
BR - Brasile 243
HK - Hong Kong 229
DE - Germania 215
TR - Turchia 196
DK - Danimarca 152
FI - Finlandia 132
CI - Costa d'Avorio 85
KR - Corea 81
GB - Regno Unito 73
FR - Francia 56
MA - Marocco 45
IN - India 30
BE - Belgio 17
NL - Olanda 17
JP - Giappone 10
CA - Canada 8
PL - Polonia 7
AZ - Azerbaigian 6
DZ - Algeria 6
AR - Argentina 5
BD - Bangladesh 5
EU - Europa 5
RO - Romania 5
VE - Venezuela 5
AT - Austria 4
CO - Colombia 4
PK - Pakistan 4
ZA - Sudafrica 4
ES - Italia 3
KG - Kirghizistan 3
MX - Messico 3
TN - Tunisia 3
UZ - Uzbekistan 3
CZ - Repubblica Ceca 2
HN - Honduras 2
IQ - Iraq 2
JM - Giamaica 2
PE - Perù 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
PA - Panama 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
TW - Taiwan 1
VN - Vietnam 1
Totale 9.297
Salva come PNG Salva come JPEG
Città #
Chandler 629
Fairfield 497
Jacksonville 468
Ashburn 361
Des Moines 351
Dublin 302
Boardman 291
Wilmington 259
Hong Kong 229
Woodbridge 227
New York 195
Seattle 189
Singapore 179
Houston 175
Ann Arbor 159
Cambridge 149
Lawrence 114
Princeton 114
Centro 105
San Mateo 104
Abidjan 84
The Dalles 67
Turin 65
Moscow 64
Beijing 59
San Diego 48
Helsinki 40
Ancona 33
Washington 32
Los Angeles 28
Pune 23
London 19
Guangzhou 17
Wuhan 17
Brussels 16
Turku 15
Munich 13
Shanghai 13
São Paulo 13
Norwalk 12
Santa Clara 11
Izmir 10
Nuremberg 10
Kilburn 9
Amsterdam 8
Cagliari 8
Chicago 8
Cupra Marittima 8
New Bedfont 8
Wuxi 8
Belo Horizonte 7
Curitiba 7
Milan 7
Rio de Janeiro 7
Baku 6
Dallas 6
Hangzhou 6
Jiaxing 6
Redmond 6
Rome 6
Fayetteville 5
Kagoya 5
Porto Alegre 5
San Francisco 5
Toronto 5
Warsaw 5
Campinas 4
Changsha 4
Clifton 4
Fermignano 4
Fortaleza 4
Guarulhos 4
Prescot 4
Redwood City 4
Shenzhen 4
Vienna 4
Yiwu 4
Zhengzhou 4
Acton 3
Atlanta 3
Bishkek 3
Bogotá 3
Brasília 3
Buffalo 3
Falconara Marittima 3
Florence 3
Foshan 3
Fuzhou 3
Hounslow 3
Istanbul 3
Joinville 3
Laurel 3
Modena 3
Nanjing 3
Porto 3
Suzhou 3
Torre Del Greco 3
Wuhu 3
Bauru 2
Bom Despacho 2
Totale 6.069
Salva come PNG Salva come JPEG
Nome #
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 141
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 139
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 132
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 126
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 124
Optimal management of resected gastric cancer 118
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 117
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 117
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 116
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 110
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 107
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 106
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 105
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 104
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 103
Adjuvant treatment after surgical resection 103
5-Fluorouracil pharmacogenomics: still rocking after all these years? 102
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 102
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 102
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 101
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 97
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 95
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 95
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 95
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 95
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 94
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 94
Benefits and limitations of a multidisciplinary approach in cancer patient management 93
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 92
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 92
BRAF-mutant colorectal cancer, a different breed evolving 91
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 91
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 89
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 89
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 89
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 88
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 88
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 88
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 88
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 88
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 87
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 87
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 87
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 85
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 84
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 84
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 83
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 82
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase 82
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 80
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 80
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 80
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 80
Novel perspectives for the treatment of gastric cancer: From a global approach to a personalized strategy 79
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 79
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan 78
Panitumumab for the treatment of metastatic colorectal cancer: A review 77
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 77
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 77
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 77
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study 77
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 76
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 76
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 76
Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: biological and clinical implications 75
Trattamento del carcinoma del pancreas. Attualità e prospettive 75
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 75
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab 74
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study 74
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 74
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 73
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 73
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 73
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 72
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 71
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 71
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 70
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 70
Gastric cancer: Therapeutic choices in advanced disease 70
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 70
From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy 69
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 68
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. 67
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 67
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? 66
Selecting the best treatment for an individual patient. 66
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 65
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 64
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 63
Identificazione di markers prognostici in pazienti con carcinoma colo-rettale metastatico trattati con Regorafenib 63
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 62
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 62
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 61
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 61
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 60
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 60
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib 59
Maintenance therapy for metastatic colorectal cancer 58
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. 58
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 57
Totale 8.452
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020189 0 0 0 0 0 0 0 0 0 0 35 154
2020/20211.804 109 173 216 101 249 121 108 135 142 197 150 103
2021/2022903 74 200 20 19 6 60 34 58 62 112 98 160
2022/20232.093 133 250 137 143 121 513 1 100 440 25 192 38
2023/20241.163 175 25 100 132 165 319 12 41 2 27 19 146
2024/20252.014 316 191 62 42 126 101 242 92 460 212 170 0
Totale 9.556